Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Free-standing ambulatory endoscopic transthoracic sympathectomy made with a urological resectoscope.

Noguera MA, Romero CA, Martinez AG, Rotger ML, Roman HDS, Espeche FA.

J Minim Access Surg. 2018 Sep 3. doi: 10.4103/jmas.JMAS_135_18. [Epub ahead of print]

2.

The Antiviral Activity of the Cellular Glycoprotein LGALS3BP/90K Is Species Specific.

Lodermeyer V, Ssebyatika G, Passos V, Ponnurangam A, Malassa A, Ewald E, Stürzel CM, Kirchhoff F, Rotger M, Falk CS, Telenti A, Krey T, Goffinet C.

J Virol. 2018 Jun 29;92(14). pii: e00226-18. doi: 10.1128/JVI.00226-18. Print 2018 Jul 15.

3.

Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.

Aouri M, Barcelo C, Guidi M, Rotger M, Cavassini M, Hizrel C, Buclin T, Decosterd LA, Csajka C; Swiss HIV Cohort Study.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e00899-16. doi: 10.1128/AAC.00899-16. Print 2017 Jan.

4.

Identification of Siglec-1 null individuals infected with HIV-1.

Martinez-Picado J, McLaren PJ, Erkizia I, Martin MP, Benet S, Rotger M, Dalmau J, Ouchi D, Wolinsky SM, Penugonda S, Günthard HF, Fellay J, Carrington M, Izquierdo-Useros N, Telenti A.

Nat Commun. 2016 Aug 11;7:12412. doi: 10.1038/ncomms12412.

5.

Contribution of Genetic Background and Clinical Risk Factors to Low-Trauma Fractures in Human Immunodeficiency Virus (HIV)-Positive Persons: The Swiss HIV Cohort Study.

Junier T, Rotger M, Biver E, Ledergerber B, Barceló C, Bartha I, Kovari H, Schmid P, Fux C, Bernasconi E, Brun Del Re C, Weber R, Fellay J, Tarr PE.

Open Forum Infect Dis. 2016 May 18;3(2):ofw101. doi: 10.1093/ofid/ofw101. eCollection 2016 Apr.

6.

Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.

Barceló C, Gaspar F, Aouri M, Panchaud A, Rotger M, Guidi M, Cavassini M, Buclin T, Decosterd LA, Csajka C; Swiss HIV Cohort Study.

J Antimicrob Chemother. 2016 Jul;71(7):1933-42. doi: 10.1093/jac/dkw050. Epub 2016 Mar 29.

PMID:
27029846
7.

Privacy-preserving genomic testing in the clinic: a model using HIV treatment.

McLaren PJ, Raisaro JL, Aouri M, Rotger M, Ayday E, Bartha I, Delgado MB, Vallet Y, Günthard HF, Cavassini M, Furrer H, Doco-Lecompte T, Marzolini C, Schmid P, Di Benedetto C, Decosterd LA, Fellay J, Hubaux JP, Telenti A.

Genet Med. 2016 Aug;18(8):814-22. doi: 10.1038/gim.2015.167. Epub 2016 Jan 14.

8.

In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.

Aouri M, Barcelo C, Ternon B, Cavassini M, Anagnostopoulos A, Yerly S, Hugues H, Vernazza P, Günthard HF, Buclin T, Telenti A, Rotger M, Decosterd LA; Swiss HIV Cohort Study.

Drug Metab Dispos. 2016 Jan;44(1):151-61. doi: 10.1124/dmd.115.065839. Epub 2015 Nov 9.

PMID:
26553012
9.

Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis.

Cummins NW, Neuhaus J, Chu H, Neaton J, Wyen C, Rockstroh JK, Skiest DJ, Boyd MA, Khoo S, Rotger M, Telenti A, Weinshilboum R, Badley AD; INSIGHT Study Group.

EBioMedicine. 2015 May 12;2(7):706-12. doi: 10.1016/j.ebiom.2015.05.012. eCollection 2015 Jul.

10.

Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.

Kovari H, Russmann S, Ledergerber B, Müller D, Rotger M, Velli P, Cavassini M, Ambrosioni J, Bregenzer A, Stöckle M, Bernasconi E, Rauch A, Speck RF; Swiss HIV Cohort Study.

PLoS One. 2015 Jul 28;10(7):e0133879. doi: 10.1371/journal.pone.0133879. eCollection 2015.

11.

Vitamin D time profile based on the contribution of non-genetic and genetic factors in HIV-infected individuals of European ancestry.

Guidi M, Foletti G, McLaren P, Cavassini M, Rauch A, Tarr PE, Lamy O, Panchaud A, Telenti A, Csajka C, Rotger M; Swiss HIV Cohort Study.

Antivir Ther. 2015;20(3):261-9. doi: 10.3851/IMP2823. Epub 2014 Jul 17.

12.

Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.

Arab-Alameddine M, Lubomirov R, Fayet-Mello A, Aouri M, Rotger M, Buclin T, Widmer N, Gatri M, Ledergerber B, Rentsch K, Cavassini M, Panchaud A, Guidi M, Telenti A, Décosterd LA, Csajka C; Swiss HIV Cohort Study.

J Antimicrob Chemother. 2014 Sep;69(9):2489-98. doi: 10.1093/jac/dku131. Epub 2014 May 12.

13.

Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression.

Dalmau J, Rotger M, Erkizia I, Rauch A, Reche P, Pino M, Esteve A, Palou E, Brander C, Paredes R, Phung P, Clotet B, Telenti A, Martinez-Picado J, Prado JG; CoRP Study Group.

AIDS. 2014 Jun 1;28(9):1261-72. doi: 10.1097/QAD.0000000000000293.

14.

SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage.

Clifford R, Louis T, Robbe P, Ackroyd S, Burns A, Timbs AT, Wright Colopy G, Dreau H, Sigaux F, Judde JG, Rotger M, Telenti A, Lin YL, Pasero P, Maelfait J, Titsias M, Cohen DR, Henderson SJ, Ross MT, Bentley D, Hillmen P, Pettitt A, Rehwinkel J, Knight SJ, Taylor JC, Crow YJ, Benkirane M, Schuh A.

Blood. 2014 Feb 13;123(7):1021-31. doi: 10.1182/blood-2013-04-490847. Epub 2013 Dec 12.

15.

Communication: Evidence of structural phase transitions in silicalite-1 by infrared spectroscopy.

Ballandras A, Weber G, Paulin C, Bellat JP, Rotger M.

J Chem Phys. 2013 Sep 7;139(9):091103. doi: 10.1063/1.4819080.

PMID:
24028095
16.

Efavirenz intoxication due to a new CYP2B6 constellation.

Anagnostopoulos A, Rotger M, Aouri M, Kuster SP, Telenti A, Décosterd LA, Günthard HF.

Antivir Ther. 2013;18(5):739-43. doi: 10.3851/IMP2571. Epub 2013 May 2.

PMID:
23640958
17.

Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.

Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, van 't Wout AB, Lubomirov R, Colombo S, Martinez R, Rauch A, Günthard HF, Neuhaus J, Wentworth D, van Manen D, Gras LA, Schuitemaker H, Albini L, Torti C, Jacobson LP, Li X, Kingsley LA, Carli F, Guaraldi G, Ford ES, Sereti I, Hadigan C, Martinez E, Arnedo M, Egaña-Gorroño L, Gatell JM, Law M, Bendall C, Petoumenos K, Rockstroh J, Wasmuth JC, Kabamba K, Delforge M, De Wit S, Berger F, Mauss S, de Paz Sierra M, Losso M, Belloso WH, Leyes M, Campins A, Mondi A, De Luca A, Bernardino I, Barriuso-Iglesias M, Torrecilla-Rodriguez A, Gonzalez-Garcia J, Arribas JR, Fanti I, Gel S, Puig J, Negredo E, Gutierrez M, Domingo P, Fischer J, Fätkenheuer G, Alonso-Villaverde C, Macken A, Woo J, McGinty T, Mallon P, Mangili A, Skinner S, Wanke CA, Reiss P, Weber R, Bucher HC, Fellay J, Telenti A, Tarr PE; MAGNIFICENT Consortium; INSIGHT; Swiss HIV Cohort Study.

Clin Infect Dis. 2013 Jul;57(1):112-21. doi: 10.1093/cid/cit196. Epub 2013 Mar 26.

18.

Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study.

Dobrinas M, Crettol S, Oneda B, Lahyani R, Rotger M, Choong E, Lubomirov R, Csajka C, Eap CB.

Pharmacogenet Genomics. 2013 Feb;23(2):84-93. doi: 10.1097/FPC.0b013e32835cb2e2.

PMID:
23249875
19.

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.

Lubomirov R, Arab-Alameddine M, Rotger M, Fayet-Mello A, Martinez R, Guidi M, di Iulio J, Cavassini M, Günthard HF, Furrer H, Marzolini C, Bernasconi E, Calmy A, Buclin T, Decosterd LA, Csajka C, Telenti A; Swiss HIV Cohort Study.

Pharmacogenet Genomics. 2013 Jan;23(1):9-18. doi: 10.1097/FPC.0b013e32835ade82.

PMID:
23111422
20.

Dosage optimization of treatments using population pharmacokinetic modeling and simulation.

Guidi M, Arab-Alameddine M, Rotger M, Aouri M, Telenti A, Decosterd LA, Buclin T, Csajka C; Swiss HIV Cohort Study.

Chimia (Aarau). 2012;66(5):291-5. doi: 10.2533/chimia.2012.291.

PMID:
22867538
21.

Stark spectrum simulation for X2Y4 molecules: application to the ν12 band of ethylene in a high-silica zeolite.

Sanzharov M, Rotger M, Loëte M, Boudon V, Zvereva-Loëte N, Ballandras A, Weber G.

J Chem Phys. 2012 Apr 7;136(13):134314. doi: 10.1063/1.3700342.

PMID:
22482559
22.

Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.

Arab-Alameddine M, Fayet-Mello A, Lubomirov R, Neely M, di Iulio J, Owen A, Boffito M, Cavassini M, Günthard HF, Rentsch K, Buclin T, Aouri M, Telenti A, Decosterd LA, Rotger M, Csajka C; Swiss HIV Cohort Study Group.

Antimicrob Agents Chemother. 2012 Jun;56(6):2959-66. doi: 10.1128/AAC.05424-11. Epub 2012 Feb 27.

23.

Pharmacogenomics: what is next?

di Iulio J, Rotger M.

Front Pharmacol. 2012 Jan 13;2:86. doi: 10.3389/fphar.2011.00086. eCollection 2011.

24.

Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy.

Glass TR, Rotger M, Telenti A, Decosterd L, Csajka C, Bucher HC, Günthard HF, Rickenbach M, Nicca D, Hirschel B, Bernasconi E, Wandeler G, Battegay M, Marzolini C; Swiss HIV Cohort Study.

PLoS One. 2012;7(1):e29186. doi: 10.1371/journal.pone.0029186. Epub 2012 Jan 3.

25.

Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque.

Rotger M, Dalmau J, Rauch A, McLaren P, Bosinger SE, Martinez R, Sandler NG, Roque A, Liebner J, Battegay M, Bernasconi E, Descombes P, Erkizia I, Fellay J, Hirschel B, Miró JM, Palou E, Hoffmann M, Massanella M, Blanco J, Woods M, Günthard HF, de Bakker P, Douek DC, Silvestri G, Martinez-Picado J, Telenti A.

J Clin Invest. 2011 Jun;121(6):2391-400. doi: 10.1172/JCI45235. Epub 2011 May 9.

26.

Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance.

di Iulio J, Ciuffi A, Fitzmaurice K, Kelleher D, Rotger M, Fellay J, Martinez R, Pulit S, Furrer H, Günthard HF, Battegay M, Bernasconi E, Schmid P, Hirschel B, Barnes E, Klenerman P, Telenti A, Rauch A; Swiss HIV Cohort Study.

Hepatology. 2011 May;53(5):1446-54. doi: 10.1002/hep.24263.

27.

Impact of single nucleotide polymorphisms and of clinical risk factors on new‐onset diabetes mellitus in HIV‐infected individuals.

Rotger M, Gsponer T, Martinez R, Taffé P, Elzi L, Vernazza P, Cavassini M, Bernasconi E, Hirschel B, Furrer H, Weber R, Ledergerber B, Egger M, Telenti A, Tarr PE; Swiss HIV Cohort Study.

Clin Infect Dis. 2010 Nov 1;51(9):1090-8. doi: 10.1086/656630.

28.

Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics.

Tarr PE, Rotger M, Telenti A.

Pharmacogenomics. 2010 Apr;11(4):587-94. doi: 10.2217/pgs.10.35. Review.

PMID:
20350140
29.

Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals.

Rotger M, Dang KK, Fellay J, Heinzen EL, Feng S, Descombes P, Shianna KV, Ge D, Günthard HF, Goldstein DB, Telenti A; Swiss HIV Cohort Study; Center for HIV/AIDS Vaccine Immunology.

PLoS Pathog. 2010 Feb 26;6(2):e1000781. doi: 10.1371/journal.ppat.1000781.

30.

Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study.

Rotger M, Bayard C, Taffé P, Martinez R, Cavassini M, Bernasconi E, Battegay M, Hirschel B, Furrer H, Witteck A, Weber R, Ledergerber B, Telenti A, Tarr PE; Swiss HIV Cohort Study.

Circ Cardiovasc Genet. 2009 Dec;2(6):621-8. doi: 10.1161/CIRCGENETICS.109.874412. Epub 2009 Sep 18.

PMID:
20031643
31.

CCL3L1 and HIV/AIDS susceptibility.

Urban TJ, Weintrob AC, Fellay J, Colombo S, Shianna KV, Gumbs C, Rotger M, Pelak K, Dang KK, Detels R, Martinson JJ, O'Brien SJ, Letvin NL, McMichael AJ, Haynes BF, Carrington M, Telenti A, Michael NL, Goldstein DB.

Nat Med. 2009 Oct;15(10):1110-2. doi: 10.1038/nm1009-1110. No abstract available.

32.

Anion-pi interactions in four-membered rings.

Estarellas C, Rotger MC, Capó M, Quiñonero D, Frontera A, Costa A, Deyà PM.

Org Lett. 2009 May 7;11(9):1987-90. doi: 10.1021/ol900470r.

PMID:
19344181
33.

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.

di Iulio J, Fayet A, Arab-Alameddine M, Rotger M, Lubomirov R, Cavassini M, Furrer H, Günthard HF, Colombo S, Csajka C, Eap CB, Decosterd LA, Telenti A; Swiss HIV Cohort Study.

Pharmacogenet Genomics. 2009 Apr;19(4):300-9. doi: 10.1097/FPC.0b013e328328d577.

PMID:
19238117
34.

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.

Arab-Alameddine M, Di Iulio J, Buclin T, Rotger M, Lubomirov R, Cavassini M, Fayet A, Décosterd LA, Eap CB, Biollaz J, Telenti A, Csajka C; Swiss HIV Cohort Study.

Clin Pharmacol Ther. 2009 May;85(5):485-94. doi: 10.1038/clpt.2008.271. Epub 2009 Feb 18.

PMID:
19225447
35.

[General concepts and study methods in pharmacogenetics].

Lubomirov R, Telenti A, Rotger M.

Enferm Infecc Microbiol Clin. 2008 May;26 Suppl 6:4-9. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2008 Oct;26(8):536.

PMID:
18680690
36.

The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir.

Colombo S, Rauch A, Rotger M, Fellay J, Martinez R, Fux C, Thurnheer C, Günthard HF, Goldstein DB, Furrer H, Telenti A; Swiss HIV Cohort Study.

J Infect Dis. 2008 Sep 15;198(6):864-7. doi: 10.1086/591184. Erratum in: J Infect Dis. 2008 Nov 1;198(9):1415.

37.

Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?

Rotger M, Telenti A.

Eur J Clin Pharmacol. 2008 Apr;64(4):335-6. doi: 10.1007/s00228-007-0440-z. Epub 2008 Jan 11. No abstract available.

PMID:
18188549
38.

Promoter polymorphisms and allelic imbalance in ABCB1 expression.

Loeuillet C, Weale M, Deutsch S, Rotger M, Soranzo N, Wyniger J, Lettre G, Dupré Y, Thuillard D, Beckmann JS, Antonarakis SE, Goldstein DB, Telenti A.

Pharmacogenet Genomics. 2007 Nov;17(11):951-9.

PMID:
18075465
39.

Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7.

Rotger M, Saumoy M, Zhang K, Flepp M, Sahli R, Decosterd L, Telenti A; Swiss HIV Cohort Study.

Pharmacogenet Genomics. 2007 Oct;17(10):885-90.

PMID:
17885627
40.

Does tenofovir influence efavirenz pharmacokinetics?

Rotger M, Colombo S, Furrer H, Décosterd L, Buclin T, Telenti A.

Antivir Ther. 2007;12(1):115-8.

PMID:
17503755
41.

Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.

Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Décosterd L, Blievernicht J, Saussele T, Günthard HF, Schwab M, Eichelbaum M, Telenti A, Zanger UM.

Clin Pharmacol Ther. 2007 Apr;81(4):557-66. Epub 2007 Jan 18.

PMID:
17235330
42.

Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.

Rotger M, Csajka C, Telenti A.

Curr HIV/AIDS Rep. 2006 Sep;3(3):118-25. Review.

PMID:
16970838
43.

Thrombin-induced contraction in alveolar epithelial cells probed by traction microscopy.

Gavara N, Sunyer R, Roca-Cusachs P, Farré R, Rotger M, Navajas D.

J Appl Physiol (1985). 2006 Aug;101(2):512-20. Epub 2006 May 4.

44.

Noninvasive detection of expiratory flow limitation in COPD patients during nasal CPAP.

Dellacà RL, Rotger M, Aliverti A, Navajas D, Pedotti A, Farré R.

Eur Respir J. 2006 May;27(5):983-91. Epub 2006 Jan 30.

45.

Probing mechanical properties of living cells by atomic force microscopy with blunted pyramidal cantilever tips.

Rico F, Roca-Cusachs P, Gavara N, Farré R, Rotger M, Navajas D.

Phys Rev E Stat Nonlin Soft Matter Phys. 2005 Aug;72(2 Pt 1):021914. Epub 2005 Aug 29.

PMID:
16196611
46.

Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia.

Rotger M, Taffe P, Bleiber G, Gunthard HF, Furrer H, Vernazza P, Drechsler H, Bernasconi E, Rickenbach M, Telenti A; Swiss HIV Cohort Study.

J Infect Dis. 2005 Oct 15;192(8):1381-6. Epub 2005 Sep 9.

47.

Phenotypic and genotypic mupirocin resistance among Staphylococci causing prosthetic joint infection.

Rotger M, Trampuz A, Piper KE, Steckelberg JM, Patel R.

J Clin Microbiol. 2005 Aug;43(8):4266-8.

48.

In vitro and in vivo evaluations of the activities of lauric acid monoester formulations against Staphylococcus aureus.

Rouse MS, Rotger M, Piper KE, Steckelberg JM, Scholz M, Andrews J, Patel R.

Antimicrob Agents Chemother. 2005 Aug;49(8):3187-91.

49.

Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo.

Colombo S, Soranzo N, Rotger M, Sprenger R, Bleiber G, Furrer H, Buclin T, Goldstein D, Décosterd L, Telenti A; Swiss HIV Cohort Study.

Pharmacogenet Genomics. 2005 Sep;15(9):599-608.

PMID:
16041239
50.

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.

Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz J, Décosterd L, Telenti A; Swiss HIV Cohort Study.

Pharmacogenet Genomics. 2005 Jan;15(1):1-5.

PMID:
15864119

Supplemental Content

Loading ...
Support Center